Similar articles

• An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.

  Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D. Anton RF, et al. Arch Gen Psychiatry. 2008 Feb;65(2):135-44. doi: 10.1001/archpsyc.65.2.135. Arch Gen Psychiatry. 2008. PMID: 18250251 Free PMC article. Clinical Trial.
• The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers.

  Mitchell JM, Fields HL, White RL, Meadoff TM, Joslyn G, Rowbotham MC. Mitchell JM, et al. J Clin Psychopharmacol. 2007 Feb;27(1):112-5. doi: 10.1097/JCP.0b013e31802e68b0. J Clin Psychopharmacol. 2007. PMID: 17224736 Clinical Trial. No abstract available.
• Preserved DNA from past clinical trials yields new information about a subtype of alcoholism.

  O'Brien CP. O'Brien CP. Curr Psychiatry Rep. 2008 Oct;10(5):375-6. doi: 10.1007/s11920-008-0060-z. Curr Psychiatry Rep. 2008. PMID: 18803909 No abstract available.
• The μ-opioid receptor and treatment response to naltrexone.

  Thorsell A. Thorsell A. Alcohol Alcohol. 2013 Jul-Aug;48(4):402-8. doi: 10.1093/alcalc/agt030. Epub 2013 Mar 29. Alcohol Alcohol. 2013. PMID: 23543091 Review.
• Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.

  Ray LA, Chin PF, Miotto K. Ray LA, et al. CNS Neurol Disord Drug Targets. 2010 Mar;9(1):13-22. doi: 10.2174/187152710790966704. CNS Neurol Disord Drug Targets. 2010. PMID: 20201811 Review.